share_log

Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Truex Samantha

SEC announcement ·  Apr 4 04:13
Summary by Futu AI
Samantha Truex, a director and 10% owner of Avalo Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per a Form 3 submission dated March 28, 2024. The form, which was signed on April 3, 2024, by Donald R. Reynolds by power of attorney, indicates that no securities are beneficially owned. This filing is in accordance with Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 and is a standard requirement for directors and significant shareholders to report their ownership of a company's securities.
Samantha Truex, a director and 10% owner of Avalo Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per a Form 3 submission dated March 28, 2024. The form, which was signed on April 3, 2024, by Donald R. Reynolds by power of attorney, indicates that no securities are beneficially owned. This filing is in accordance with Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 and is a standard requirement for directors and significant shareholders to report their ownership of a company's securities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.